Preliminary studies in NSCLC showed that compared with crizotinib (PF-02341066, Xalkori), an ALK/c-MET/ROS1 inhibitor that has been approved to treat patients with relapsed ALK+ NSCLC, ASP3026 is more tolerable and more potent in inhibiting EML4-ALK [20]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.